Potential role of A2A adenosine receptor in traumatic optic neuropathy

Journal of Neuroimmunology

Volumn 264, Issue 1-2, 2013, Pages 54-64

  Ahmad, Saif ^a,b   Fatteh, Nadeem ^a   El Sherbiny, Nehal M ^a,c   Naime, Mohammad ^a,f   Ibrahim, Ahmed S ^c   El Sherbini, Ahmed M ^a   El Shafey, Sally A ^a   Khan, Sohail ^d   Fulzele, Sadanand ^e   Gonzales, Joyce ^a   Liou, Gregory I ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c MANSOURA UNIVERSITY   (Egypt)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e AUGUSTA UNIVERSITY   (United States)

^f CCRUM   (India)

Author keywords

Adenosine A2A receptor; Inflammatory cytokines; MAPKinase; Microglia; Oxidative stress; Traumatic optic neuropathy

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; 2 (4 (2 CARBOXYETHYL)PHENETHYLAMINO) 5' N ETHYLCARBOXAMIDOADENOSINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2-(4-(2-CARBOXYETHYL)PHENETHYLAMINO)-5'-N-ETHYLCARBOXAMIDOADENOSINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ACTIN BINDING PROTEIN; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE RECEPTOR; AIF1 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; CASPASE 3; DRUG DERIVATIVE; GLIAL FIBRILLARY ACIDIC PROTEIN; NERVE PROTEIN; PHENETHYLAMINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL DEATH; CELL HYPOXIA; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; ENZYME ACTIVATION; IN VITRO STUDY; MALE; MICROGLIA; MOUSE; NONHUMAN; OPTIC NERVE DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RETINA CELL; RETINITIS; SIGNAL TRANSDUCTION; WILD TYPE; 2-P-[2-CARBOXYETHYL]PHENETHYLAMINO-5′-N-ETHYLCARBOXAMIDOADENOSINE; 4-(2-[7-AMINO-2-(2-FURYL)[1,2,4]TRIAZOLO[2,3-A][1,3,5]TRIAZIN-5-YLAMINO]ETHYL)PHENOL; 5′-N-ETHYLCARBOXAMIDOADENOSINE; ADENOSINE A(2A) RECEPTOR; ANIMAL; AR; C57BL MOUSE; CELL CULTURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERK; EXTRACELLULAR SIGNAL-REGULATED KINASE; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATORY CYTOKINES; MAPKINASE; METABOLISM; MITOGEN-ACTIVATED PROTEIN KINASE; OPTIC NERVE INJURY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; RETINA; ROS; SPRAGUE DAWLEY RAT; TIME; TNF-Α; TON; TRANSGENIC MOUSE; TRAUMATIC OPTIC NEUROPATHY; TUMOR NECROSIS FACTOR-Α; ANALOGS AND DERIVATIVES; DEFICIENCY; DRUG EFFECTS;

2-P-[2-CARBOXYETHYL]PHENETHYLAMINO-5′-N-ETHYLCARBOXAMIDOADENOSINE; 4-(2-[7-AMINO-2-(2-FURYL)[1,2,4]TRIAZOLO[2,3-A][1,3,5]TRIAZIN-5-YLAMINO]ETHYL)PHENOL; 5′-N-ETHYLCARBOXAMIDOADENOSINE; ADENOSINE A(2A) RECEPTOR; ADENOSINE RECEPTOR; AR; CGS21680; ELISA; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERK; EXTRACELLULAR SIGNAL-REGULATED KINASE; INFLAMMATORY CYTOKINES; LIPOPOLYSACCHARIDES; LPS; MAP KINASE; MAPKINASE; MICROGLIA; MITOGEN-ACTIVATED PROTEIN KINASE; NECA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; ROS; TNF-Α; TON; TRAUMATIC OPTIC NEUROPATHY; TUMOR NECROSIS FACTOR-Α; ZM241385;

ADENOSINE; ADENOSINE A2 RECEPTOR AGONISTS; ANIMALS; CALCIUM-BINDING PROTEINS; CASPASE 3; CELLS, CULTURED; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERCELLULAR ADHESION MOLECULE-1; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; MICROGLIA; NERVE TISSUE PROTEINS; OPTIC NERVE INJURIES; PHENETHYLAMINES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTOR, ADENOSINE A2A; RETINA; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886803287     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.09.015     Document Type: Article

References (40)

1. Al-Shabrawey M., Rojas M., Sanders T., Behzadian A., El-Remessy A., Bartoli M., et al. Role of NADPH oxidase in retinal vascular inflammation. Invest. Ophthalmol. Vis. Sci. 2008, 49:3239-3244.
2. Awad A.S., Huang L., Ye H., Duong E.T., Bolton W.K., Linden J., et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2006, 290:F828-F837.
3. Bhatia K., Elmarakby A.A., El-Remessy A.B., Sullivan J.C. Oxidative stress contributes to sex differences in angiotensin II-mediated hypertension in spontaneously hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 302:R274-R282.
4. Bong G.W., Rosengren S., Firestein G.S. Spinal cord adenosine receptor stimulation in rats inhibits peripheral neutrophil accumulation. The role of N-methyl-d-aspartate receptors. J. Clin. Invest. 1996, 98:2779-2785.
5. Brennan A.M., Suh S.W., Won S.J., Narasimhan P., Kauppinen T.M., Lee H., et al. NADPH oxidase is the primary source of superoxide induced by NMDA receptor activation. Nat. Neurosci. 2009, 12:857-863.
6. Chen J.F., Huang Z., Ma J., Zhu J., Moratalla R., Standaert D., et al. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 1999, 19:9192-9200.
7. Collis M.G., Hourani S.M. Adenosine receptor subtypes. Trends Pharmacol. Sci. 1993, 14:360-366.
8. Ding C., Cicuttini F., Li J., Jones G. Targeting IL-6 in the treatment of inflammatory and autoimmune diseases. Expert Opin. Investig. Drugs 2009, 18:1457-1466.
9. El-Remessy A.B., Tang Y., Zhu G., Matragoon S., Khalifa Y., Liu E.K., et al. Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. Mol. Vis. 2008, 14:2190-2203.
10. Feoktistov I., Goldstein A.E., Biaggioni I. Role of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase kinase in adenosine A2B receptor-mediated interleukin-8 production in human mast cells. Mol. Pharmacol. 1999, 55:726-734.
11. Fozard J.R., Ellis K.M., Villela Dantas M.F., Tigani B., Mazzoni L. Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur. J. Pharmacol. 2002, 438:183-188.
12. Fredholm B.B., Abbracchio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A., et al. Nomenclature and classification of purinoceptors. Pharmacol. Rev. 1994, 46:143-156.
13. Genovese T., Melani A., Esposito E., Mazzon E., Di Paola R., Bramanti P., et al. The selective adenosine A2A receptor agonist CGS 21680 reduces JNK MAPK activation in oligodendrocytes in injured spinal cord. Shock 2009, 32:578-585.
14. Gerits N., Kostenko S., Shiryaev A., Johannessen M., Moens U. Relations between the mitogen-activated protein kinase and the cAMP-dependent protein kinase pathways: comradeship and hostility. Cell. Signal. 2008, 20:1592-1607.
15. Ibrahim A.S., El-Remessy A.B., Matragoon S., Zhang W., Patel Y., Khan S., et al. Retinal microglial activation and inflammation induced by amadori-glycated albumin in a rat model of diabetes. Diabetes 2011, 60:1122-1133.
16. Ibrahim A.S., El-Shishtawy M.M., Zhang W., Caldwell R.B., Liou G.I. A((2)A) adenosine receptor (A((2)A)AR) as a therapeutic target in diabetic retinopathy. Am. J. Pathol. 2011, 178:2136-2145.
17. Inaba S., Iwai M., Tomono Y., Senba I., Furuno M., Kanno H., et al. Exaggeration of focal cerebral ischemia in transgenic mice carrying human renin and human angiotensinogen genes. Stroke 2009, 40:597-603.
18. Johnson S.M., Patel S., Bruckner F.E., Collins D.A. 5'-Nucleotidase as a marker of both general and local inflammation in rheumatoid arthritis patients. Rheumatology (Oxford) 1999, 38:391-396.
19. Jones P.A., Smith R.A., Stone T.W. Protection against kainate-induced excitotoxicity by adenosine A2A receptor agonists and antagonists. Neuroscience 1998, 85:229-237.
20. Joussen A.M., Poulaki V., Le M.L., Koizumi K., Esser C., Janicki H., et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004, 18:1450-1452.
21. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 2000, 18:621-663.
22. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996, 19:312-318.
23. Levkovitch-Verbin H. Animal models of optic nerve diseases. Eye (Lond.) 2004, 18:1066-1074.
24. Liou G.I., Auchampach J.A., Hillard C.J., Zhu G., Yousufzai B., Mian S., et al. Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. Invest. Ophthalmol. Vis. Sci. 2008, 49:5526-5531.
25. McPherson J.A., Barringhaus K.G., Bishop G.G., Sanders J.M., Rieger J.M., Hesselbacher S.E., et al. Adenosine A(2A) receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler. Thromb. Vasc. Biol. 2001, 21:791-796.
26. Milne G.R., Palmer T.M. Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. ScientificWorldJournal 2011, 11:320-339.
27. Nadeem A., Ponnoth D.S., Ansari H.R., Batchelor T.P., Dey R.D., Ledent C., et al. A2A adenosine receptor deficiency leads to impaired tracheal relaxation via NADPH oxidase pathway in allergic mice. J. Pharmacol. Exp. Ther. 2009, 330:99-108.
28. Ohta A., Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001, 414:916-920.
29. Okusa M.D., Linden J., Macdonald T., Huang L. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am. J. Physiol. 1999, 277:F404-F412.
30. Quan Y., Du J., Wang X. High glucose stimulates GRO secretion from rat microglia via ROS, PKC, and NF-kappaB pathways. J. Neurosci. Res. 2007, 85:3150-3159.
31. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 1998, 50:413-492.
32. Roe N.D., Thomas D.P., Ren J. Inhibition of NADPH oxidase alleviates experimental diabetes-induced myocardial contractile dysfunction. Diabetes Obes. Metab. 2011, 13:465-473.
33. Sheardown M.J., Knutsen L.J.S. Unexpected neuroprotection observed with the adenosine A2A receptor agonist CGS 21680. Drug Dev. Res. 1996, 39:108-114.
34. Stork P.J., Schmitt J.M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 2002, 12:258-266.
35. Sullivan G.W., Rieger J.M., Scheld W.M., Macdonald T.L., Linden J. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists. Br. J. Pharmacol. 2001, 132:1017-1026.
36. Tang X.N., Cairns B., Kim J.Y., Yenari M.A. NADPH oxidase in stroke and cerebrovascular disease. Neurol. Res. 2012, 34:338-345.
37. Wang A.L., Yu A.C., Lau L.T., Lee C., Wu le M., Zhu X., et al. Minocycline inhibits LPS-induced retinal microglia activation. Neurochem. Int. 2005, 47:152-158.
38. Wang A.L., Yu A.C., He Q.H., Zhu X., Tso M.O. AGEs mediated expression and secretion of TNF alpha in rat retinal microglia. Exp. Eye Res. 2007, 84:905-913.
39. Wurm A., Iandiev I., Hollborn M., Wiedemann P., Reichenbach A., Zimmermann H., et al. Purinergic receptor activation inhibits osmotic glial cell swelling in the diabetic rat retina. Exp. Eye Res. 2008, 87:385-393.
40. Yang Z., Day Y.J., Toufektsian M.C., Ramos S.I., Marshall M., Wang X.Q., et al. Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 2005, 111:2190-2197.